Altropane pivotal trial agreement
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Boston Life Sciences will proceed with a single pivotal trial for its Parkinson's disease radioimaging agent Altropane under a special protocol assessment. Agreement was reached after "a number of teleconferences, meetings and protocol revisions occurring over an eight-month period in which the company and FDA refined the study design," BLS says. The study will enroll at least 500 patients (250 with PD tremor, 250 with non-PD tremor). Primary analyses will evaluate Altropane's sensitivity and specificity versus that of an internist/general practitioner in distinguishing PD tremors from non-PD tremors. The agent is also in Phase II studies for diagnosis of attention deficit/hyperactivity disorder...
You may also be interested in...
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.